Enhancement of plasmid-mediated gene therapy for muscular dystrophy by directed plasmid integration.

Plasmid-mediated gene therapy can restore dystrophin expression in skeletal muscle in the mdx mouse, a model of Duchenne muscular dystrophy. However, sufficient long-term expression and distribution of dystrophin remain a hurdle for translating this technology into a viable treatment for Duchenne muscular dystrophy. To improve plasmid-mediated gene therapy for muscle diseases, we studied the effects of targeted plasmid integration using a phage integrase (phiC31) that can mediate the integration of suitably modified plasmids into the mammalian genome. Using a luciferase expression plasmid, we monitored plasmid gene expression noninvasively in living mice by bioluminescence imaging. Coinjection of an integrase plasmid resulted in 5- to 10-fold higher levels of sustained luciferase expression. Likewise, plasmid-mediated dystrophin expression in mdx muscle was enhanced by integration. Using a combination of dystrophin and luciferase plasmids, we analyzed the functional benefit of dystrophin expression in the dystrophic muscle. The expression of dystrophin slowed the loss of luciferase expression associated with muscle degeneration, and that protection was enhanced by targeted integration of the dystrophin plasmid. In the presence of integrase, dystrophin expression was distributed along a much greater length of individual fibers, and this was associated with increased protection against degenerative changes. These data demonstrate the importance of both the level and distribution of dystrophin expression to achieve therapeutic efficacy, and that the efficacy can be enhanced by targeted plasmid integration.

[1]  M. Kay,et al.  Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo , 2004, Gene Therapy.

[2]  P. Khavari,et al.  Stable nonviral genetic correction of inherited human skin disease , 2002, Nature Medicine.

[3]  S. Akira,et al.  A Toll-like receptor recognizes bacterial DNA , 2000, Nature.

[4]  G. Ciliberto,et al.  Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation , 2004, Gene Therapy.

[5]  E. Signori,et al.  Optimisation of electrotransfer of plasmid into skeletal muscle by pretreatment with hyaluronidase – increased expression with reduced muscle damage , 2001, Gene Therapy.

[6]  Q. L. Lu,et al.  A New Blocking Method for Application of Murine Monoclonal Antibody to Mouse Tissue Sections , 1998, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[7]  H. Herweijer,et al.  Progress and prospects: naked DNA gene transfer and therapy , 2003, Gene Therapy.

[8]  E. Schultz,et al.  Dystrophin expression improves myofiber survival in mdx muscle following intramuscular plasmid DNA injection. , 1993, Human molecular genetics.

[9]  A. Nishikawa,et al.  Visualization of dystrophic muscle fibers in mdx mouse by vital staining with Evans blue: evidence of apoptosis in dystrophin-deficient muscle. , 1995, Journal of biochemistry.

[10]  P. Khavari,et al.  φC31 Integrase-Mediated Nonviral Genetic Correction of Junctional Epidermolysis Bullosa , 2003 .

[11]  M. Bassik,et al.  DNA vector chemistry: The covalent attachment of signal peptides to plasmid DNA , 1998, Nature Biotechnology.

[12]  Eric C. Olivares,et al.  Nucleofection of muscle-derived stem cells and myoblasts with phiC31 integrase: stable expression of a full-length-dystrophin fusion gene by human myoblasts. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  N. Romero,et al.  Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies Part II: clinical protocol , 2002, Neuromuscular Disorders.

[14]  Eric C. Olivares,et al.  Site-specific genomic integration produces therapeutic Factor IX levels in mice , 2002, Nature Biotechnology.

[15]  Eric C. Olivares,et al.  A phage integrase directs efficient site-specific integration in human cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M. Kay,et al.  Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  C. Mann,et al.  Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse , 2003, Nature Medicine.

[18]  K. Barnhart,et al.  An improved plasmid DNA expression vector for direct injection into skeletal muscle. , 1996, Human gene therapy.

[19]  J. Nalbantoglu,et al.  Factors influencing the efficacy, longevity, and safety of electroporation-assisted plasmid-based gene transfer into mouse muscles. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  D. Wells,et al.  High-efficiency plasmid gene transfer into dystrophic muscle , 2003, Gene Therapy.

[21]  S. Cheng,et al.  High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  G. Acsadi,et al.  Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. , 1992, Human molecular genetics.

[23]  Eric C. Olivares,et al.  Phage R4 integrase mediates site-specific integration in human cells. , 2001, Gene.

[24]  F. Paillard.  CpG: the double-edged sword. , 1999, Human gene therapy.

[25]  R. Scheule,et al.  CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  M. Bureau,et al.  High-efficiency gene transfer into skeletal muscle mediated by electric pulses. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[27]  C. Higgins,et al.  Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor1α promoter , 2001, Gene Therapy.

[28]  H. Herweijer,et al.  High expression of naked plasmid DNA in muscles of young rodents. , 1997, Human molecular genetics.

[29]  Sung Ho Hahm,et al.  Retroviral gene therapy: safety issues and possible solutions. , 2005, Current gene therapy.

[30]  B. Thyagarajan,et al.  Directed evolution of a recombinase for improved genomic integration at a native human sequence. , 2001, Nucleic acids research.

[31]  H. Herweijer,et al.  Intraarterial delivery of naked plasmid DNA expressing full-length mouse dystrophin in the mdx mouse model of duchenne muscular dystrophy. , 2004, Human gene therapy.

[32]  C. Contag,et al.  Advances in in vivo bioluminescence imaging of gene expression. , 2002, Annual review of biomedical engineering.

[33]  Eric C. Olivares,et al.  Site-Specific Genomic Integration in Mammalian Cells Mediated by Phage φC31 Integrase , 2001, Molecular and Cellular Biology.